Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.

NCT04293172 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study halted prematurely, prior to enrolment of first patient.

Conditions

Sickle Cell Disease

Interventions

DRUG: Brilinta
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]